Jun. 27, 2012
Isotechnika Pharma announced on June 28, 2012 that 3SBio Inc., a leading China-based biotechnology company, has received approval from the SFDA to conduct a multi-center Phase III trial of Isotechnika’s voclosporin in China.
According to the approved protocol, this will be a Phase III, randomized, multi-center, concentration-controlled and comparison study in kidney transplant patients. Patient enrollment is expected to begin in the fall of 2012.